This study aims to assess how a polygenic risk score (PRS) reported with the results of multi-gene panel testing affects the breast cancer risk management recommendations healthcare providers make to their patients. The PRS is a score based on small genetic changes, clinical history, and family history. The PRS is used to estimate remaining lifetime risk of developing breast cancer for patients with no personal history of breast cancer and an overall negative result from MGPT.
For more information contact us at DFCC_Clinical_Research@providence.org or call (818) 748-4793
Site located at Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center.